May 2, 2011 | Laboratory Pathology, News From Dark Daily
Pathologists take note! Companion diagnostics is the driver in this transaction.
Genetic testing giant Myriad Genetics, Inc. (NASDAQ:MYGN) will pay $80 million to acquire Rules-Based Medicine (RBM) of Austin, Texas, a privately-held companion diagnostic company in a deal announced last week.
Myriad Genetics, best known to pathologists and clinical laboratory managers for its portfolio of predictive genetic cancer tests, believes its purchase of Rules-Based Medicine will give it a faster entre into companion diagnostics. RBM is a life sciences company that has well-established relationships with key therapeutic drug companies.
(more…)
Mar 23, 2011 | Digital Pathology, Laboratory News, Laboratory Pathology
Rapid gene sequencing technology will give medical laboratories a new diagnostic tool
Rapidly-evolving molecular diagnostics technology is about to trigger a major expansion in pre-conception genetic testing. In turn, this could benefit clinical laboratories and pathology groups as they begin to offer these genetic tests to help prospective parents screen their DNA for recessive gene mutations that cause 448 deadly childhood diseases in offspring.
This breakthrough medical laboratory test delivers two important benefits. First, as a universal carrier screening test, this multiplex assay greatly expands the number of diseases that can be screened at one time. Second, its next-generation sequencing (NGS) technology dramatically reduces the cost of genetic sequencing. Instead of thousands of dollars, this test only costs about $400!
(more…)
